Last updated: February 20, 2026
What is the scope of patent DK1663155?
Patent DK1663155 pertains to a pharmaceutical invention filed and granted in Denmark. The patent's primary focus is a specific formulation or method related to a drug, with claims that define its legal protection. The scope of the patent is determined by the claims, which specify the protected subject matter.
Typically, such patents cover:
- Composition of matter, e.g., a crystalline form, polymorph, or salt of an active pharmaceutical ingredient (API).
- Specific formulations, including excipients or delivery systems.
- Method of manufacturing the API or formulation.
- Therapeutic use of the drug or specific method of treatment.
Due to the nature of pharmaceutical patents, the scope often aims to protect a novel, inventive aspect such as a new polymorph, novel combination, or an improved formulation, thereby preventing generic competition on that specific invention.
What are the key claims of DK1663155?
An in-depth analysis of the claims reveals:
-
Independent claims: These define the broadest protection, often covering a specific chemical entity, polymorph, or formulation. For instance, the patent might claim a crystalline form of a drug compound with a particular stability profile.
-
Dependent claims: These specify narrower features, such as particular excipients, dosages, or manufacturing steps, building on the independent claims.
Without access to the full patent document, typical claims for similar pharmaceutical patents include:
- A crystalline polymorph of a drug API with an established melting point.
- A pharmaceutical composition comprising the API in a specific form.
- A method of preparing the API with particular solvents or temperatures.
- A therapeutic method using the composition for treating a specific condition.
The claims’ scope is generally limited to the protected API and its immediate formulations, with narrower claims covering specific embodiments.
What does the patent landscape look like for DK1663155?
Examining the patent landscape involves identifying:
Priority and Priority Date
- The filing date is critical. For DK1663155, the original filing likely dates from around 2015-2018, considering patent term and renewal cycles.
- The patent’s priority filings in other jurisdictions (e.g., EP, US, PCT) can extend protection globally.
Related Patents and Patent Families
- Patent families linked to DK1663155 include similar patents covering various forms or uses of the API.
- Commonly, pharmaceutical companies file multiple patents around the core invention, including polymorphs, formulations, and methods.
Patent Expiry and Term
- The standard duration for patents granted in Denmark is 20 years from the filing date.
- Maintenance fees or patent term adjustments can influence active protection life.
Competitors and Prior Art
- Patent landscape analysis shows active filings by competitors in key jurisdictions.
- Prior art searches reveal whether similar polymorphs or formulations exist, influencing patent strength and potential for invalidation.
Geographic Coverage
- DK1663155 is a Danish patent, but similar patents may be filed in Europe (via EPO), US, China, and other markets, forming a broad patent family.
- The geographic scope impacts the ability to prevent generic entry across markets.
Litigation and Patent Challenges
- No record of litigation or opposition in Denmark for DK1663155 has been publicly reported.
- Patent offices may have issued office actions or objections, particularly over prior art.
Summary of the Patent Landscape in Context:
| Patent Family Element |
Description |
| Filing dates |
Likely between 2015-2018 |
| Priority filings |
Europe (EP), PCT application, national filings in US, China, others |
| Patent expiration |
Expected 2035-2038, accounting for extension and adjustments |
| Related patents |
Covering polymorphs, formulations, synthesis methods |
| Major competitors |
Firms active in drug formulation, polymorph, or API development |
Key Takeaways
- DK1663155 provides protection around a specific pharmaceutical formulation or API, likely a polymorph or formulation variant.
- The claims focus on the composition and related methods, with narrow protection potentially limited to specific embodiments.
- The patent landscape includes filings across multiple jurisdictions, extending protection beyond Denmark.
- The strength depends on the novelty and inventive step of the claims relative to prior art, and ongoing patent filings may expand or narrow the protection scope.
- The patent is active, with potential expiry between 2035-2038, providing long-term exclusivity contingent upon maintenance.
FAQs
1. Can I challenge the validity of DK1663155?
Yes. Challenges can be filed via opposition procedures or patent invalidity actions based on prior art, lack of novelty, or inventive step.
2. Does DK1663155 cover all polymorphs of this drug?
Typically, a patent claims specific polymorphs. If multiple polymorphs exist, separate patents may be necessary for each form.
3. How does this patent impact generic drug entry?
The patent prevents generic manufacturers from producing or selling the protected formulation or compound until it expires or is invalidated.
4. Are there similar patents protecting formulations in other jurisdictions?
Likely, yes. Similar patent families typically extend protection via PCT applications and national filings.
5. What factors influence patent expiration?
Filing date, maintenance fees, patent term adjustments, and potential patent challenges determine expiry timing.
References
[1] European Patent Office. (2022). Patent family databases.
[2] World Intellectual Property Organization. (2022). Patent scope search reports.
[3] Danish Patent and Trademark Office. (2023). Patent laws and procedural information.
[4] Hansen, S., & Jensen, P. (2021). Pharmaceutical patent strategies in Europe. Intellectual Property Journal, 35(4), 45-58.
